Sacituzumab govitecan plus pembrolizumab outperforms chemotherapy in PD-L1+ metastatic TNBC

Replacing chemotherapy with sacituzumab govitecan in combination with pembrolizumab significantly improves progression-free survival (PFS) and duration of response in programmed cell death-ligand 1 (PD-L1)-positive advanced triple-negative breast cancer (TNBC), results from the phase 3 ASCENT-04/KEYNOTE-D19 trial revealed. The safety profile of sacituzumab govitecan was manageable. Dr Sara M. Tolaney (Dana-Farber Cancer Institute and Harvard Medical School, MA) introduced: “A significant portion of patients with metastatic TNBC do not receive treatment beyond the first line due to clinical deterioration or death. This emphasises the urgent need for more effective and tolerable first-line options.” Sacituzumab govitecan, a first-in-class anti-trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, was recently confirmed as an effective second-line treatment option in pretreated metastatic TNBC [1]. The current phase 3 ASCENT-04/KEYNOTE-D19 (

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 30 July 2025